Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–1 of 1 stories
FDA approves Breyanzi (lisocabtagene maraleucel) as the first CAR T-cell therapy for marginal zone lymphoma in the U.S. This approval marks a significant advancement in treatment options for patients with this rare blood cancer.
Read full storyGet the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.